Israeli Companies Barred from UAE BioTech Symposium
In a significant move impacting the BioTech sector, it has been announced that Israeli companies will not be able to participate in the quarterly UAE BioTech Symposium. This esteemed event, which involves roadshows across various Gulf States, is poised to restrict access for firms from Israel.
Background on the UAE BioTech Symposium
The UAE BioTech Symposium serves as a platform for innovation in the BioTech industry, focusing on advancements and research that promote health and sustainability. The symposium is dedicated to the memory of Nobel Laureate Professor Dr. Günter Blobel, known for his contributions to the field and commitment to fostering peace through science.
Mandate of Exclusion
Dr. Kambiz Shekdar, PhD, who chairs the AmCham Abu Dhabi BioTech Committee, emphasized the exclusion policy stating, "As Chairman, I mandate that Israeli companies are not allowed." This decision highlights the geopolitical tensions that can influence business interactions and foster a climate of restriction.
Upcoming Event Details
The next UAE BioTech Symposium is scheduled to take place from November 2 to 6, 2024, in Abu Dhabi and Dubai. While the symposium primarily aims to connect various international BioTech leaders, the exclusion of Israeli companies places a spotlight on the intricate political landscape. Participants who wish to register for this initiative can find information through AmCham Abu Dhabi.
Personal Reflections from Dr. Shekdar
Dr. Shekdar shared poignant memories regarding his mentorship with the late Professor Blobel, who influenced his scientific career significantly. He recounted notable moments from Blobel’s past, recalling harrowing experiences during WWII and his family’s escape during the bombings. Blobel's legacy is not just about his scientific achievements but also about his vision for unity and collaboration across cultures.
The Impact of Historical Context
Blobel often reflected on the destruction of Dresden and its implications. He emphasized humanitarian values, demonstrating that collaborative effort and understanding are key to unlocking human potential. Dr. Shekdar inherits this legacy as he leads initiatives that strive for advancements in drug discovery and BioTech innovation.
About Dr. Kambiz Shekdar and His Role in BioTech
Dr. Kambiz Shekdar is an esteemed figure in the BioTech community, credited for his invention of the innovative Chromovert® Technology during his formative years at The Rockefeller University. His career trajectory includes pivotal roles in transitioning scientific advancements into practical applications within the UAE. Dr. Shekdar continues to work towards establishing a significant BioTech sector, nurturing collaborations with both Emirati stakeholders and international companies.
Future of the UAE BioTech Sector
The UAE aims to position itself as a hub for advanced Biotechnological research. Through collaborations and strategic partnerships, there is an ongoing effort to attract international BioTech ventures, especially from the United States. The AmCham Abu Dhabi BioTech Committee plays a crucial role in this initiative, pushing for a thriving environment for innovation.
Frequently Asked Questions
1. Why are Israeli companies excluded from the UAE BioTech Symposium?
The exclusion stems from geopolitical tensions, as mandated by the AmCham Abu Dhabi BioTech Committee chaired by Dr. Kambiz Shekdar.
2. What is the UAE BioTech Symposium?
The UAE BioTech Symposium is a quarterly event focusing on innovations in the BioTech sector and encourages collaboration among industry leaders.
3. Who is Dr. Kambiz Shekdar?
Dr. Kambiz Shekdar is the chairman of the AmCham Abu Dhabi BioTech Committee and an inventor known for his work in biotechnology.
4. When is the next UAE BioTech Symposium?
The next symposium is scheduled to take place from November 2 to 6, 2024, in Abu Dhabi and Dubai.
5. How does the symposium impact international BioTech companies?
The symposium serves as a major networking opportunity, although the exclusion of certain firms impacts the diversity of participation.
